Home committees step up investigation into FDA approval of controversial Alzheimer’s drug

Home committees step up investigation into FDA approval of controversial Alzheimer’s drug

The company’s June 7 accelerated approval of the medicine, the primary Alzheimer’s drug cleared in virtually twenty years, was welcomed by some advocates and docs as a step ahead in treating the devastating illness however strongly criticized by many consultants who say the medicine hasn’t been proven to be efficient. The choice was particularly controversial as a result of the company’s personal outdoors consultants had really useful towards approval. Some medical facilities have refused to supply the drug, which carries an inventory worth of $56,000 a 12 months per affected person.

Source link